Skip to content

Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01991119
Enrollment
98
Registered
2013-11-25
Start date
2011-05-31
Completion date
2013-10-31
Last updated
2013-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial fibrillation, Propafenone, Dronedarone

Brief summary

the purpose of this study is to compare the ability of propafenone and dronedarone to maintain sinus rhythm after DC cardioversion

Detailed description

Atrial fibrillation is the most common arrhythmia requiring continuous therapy. Conversion to and maintenance of sinus rhythm is important. Propafenone and dronedarone has been used as treatment for maintenance of sinus rhythm after DC cardioversion. But there are no direct comparison study. The purpose of this study is to compare the ability of propafenone and dronedarone to maintain sinus rhythm after DC cardioversion.

Interventions

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* a patient with persistent atrial fibrillation who received successful DC cardioversion

Exclusion criteria

* prior amiodarone use * NYHA class III or IV heart failure * Left ventricular ejection fraction \< 35% * second or third AV block * sick sinus syndrome * heart rate \< 50 beat per minute * myocardiac infarction within 3 months * pregnant women * severe hepatic dysfunction * QT prolongation \> 500ms or PR interval \> 180ms * history of hypersensitivity for drug

Design outcomes

Primary

MeasureTime frame
recurrence of atrial fibrillation6 month

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026